Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

The announcement was widely seen as a vote of confidence in companies like Mitsubishi Corp. and Marubeni Corp., which have gained global prominence for their diversified business models.

Marubeni aims for net profit of more than $4 bln in FY 2027/28 Marubeni said on Wednesday it is aiming for a net profit of more than 620 billion yen ($4 billion) in fiscal 2027/2028 along with a ...

A sudden power outage during a concert is an unlikely backdrop for a corporate advert, yet Marubeni's latest campaign, featuring J-Pop sensation Ado, manages to turn this disruption into a compelling, ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

For example, Takeda is investigating novel delivery devices and formulations that have the potential to significantly reduce the time and burden of administration, including a completely novel ...

Takeda, the Japan-based biopharmaceutical company, inaugurated its Innovation Capabilities Centre (ICC) on Wednesday at the Bhartiya City IT Park in Bengaluru. By the end of 2025, the company aims to ...

However, it announced on June 8 its policy to acquire North Pacific Seafoods, Inc. (NPSI), owned by the Marubeni Group. As a result, Marubeni, which has engaged in the North American business for many ...